Hepatitis D is a unique viral liver infection that only occurs in people who already have hepatitis B. Unlike other forms of hepatitis, this virus cannot survive on its own—it needs hepatitis B to replicate and spread. When both viruses are present together, the liver damage can progress more quickly and severely than with hepatitis B alone, increasing the risk of serious complications like cirrhosis and liver failure.
Key points
check_circleHepatitis D is unique because it can only infect people who also have hepatitis B—it's the only human virus that requires another virus to survive
check_circlePegylated interferon is currently the main approved treatment but works in only about half of patients and can cause significant side effects
check_circleBulevirtide, a groundbreaking entry inhibitor approved in Europe, represents the first hepatitis D-specific treatment with a better safety profile than interferon
check_circleNew combination therapies being tested in trials like SOLSTICE show response rates above 50 percent by attacking the virus through multiple pathways
check_circleGetting vaccinated against hepatitis B is the only way to prevent hepatitis D since the two viruses are inseparably linked
check_circleSuperinfection (getting hepatitis D after already having hepatitis B) is more dangerous than coinfection and more likely to become chronic
check_circleHepatitis D progresses to cirrhosis and liver cancer faster than hepatitis B alone, making early detection and treatment crucial
check_circleMultiple new drug classes including RNA interference therapies and prenylation inhibitors are in various stages of clinical testing, offering hope for better treatments in the near future
Understanding Treatment Goals for Hepatitis D
Managing hepatitis D involves multiple challenges because this virus behaves differently from other hepatitis infections. The main goal of treatment is to slow down the damage happening to the liver and prevent the disease from getting worse. Healthcare providers also focus on helping patients maintain their quality of life by reducing symptoms and preventing complications like cirrhosis (severe scarring of the liver), liver failure, and liver cancer.
Treatment decisions depend on several factors, including how severe the liver disease is, whether the patient has other health conditions, and how the body responds to medications. Some people with acute hepatitis D infections may recover without treatment, but those with chronic infection—meaning the virus stays in the body for more than six months—usually need medical intervention.
The approach to hepatitis D varies based on whether someone has both hepatitis B and D at the same time (called coinfection) or develops hepatitis D after already having hepatitis B (called superinfection). Superinfection tends to be more serious because it often leads to chronic, long-lasting disease that progresses rapidly.
Currently, medical societies recognize certain standard treatments for hepatitis D, though options remain limited compared to other liver diseases. At the same time, researchers are actively testing new therapies in clinical trials, offering hope that more effective treatments will become available in the future.
Standard Treatment Options
For many years, the main treatment available for chronic hepatitis D has been pegylated interferon alfa (often written as peg-IFNα or PEG-IFN). This medication is a protein that helps the body's immune system fight viral infections. When injected, it encourages immune cells to attack the virus more effectively.
Pegylated interferon alfa is typically given as a weekly injection under the skin. Clinical guidelines recommend treatment for at least 48 weeks (almost a year) for the best chance of success. However, even with this long treatment period, results are mixed. Studies show that only about 23 to 57 percent of patients respond well to this therapy, and unfortunately, around half of those who do respond experience the virus coming back after treatment stops.
The effectiveness of pegylated interferon varies depending on how someone acquired the infection. For people with coinfection (getting both viruses at once), the treatment is more likely to clear the hepatitis D virus from the body. Those with superinfection (getting hepatitis D after already having hepatitis B) have a harder time eliminating the virus completely and may need to manage both conditions as long-term illnesses.
People with advanced liver disease, especially those whose liver has stopped working properly (called decompensated cirrhosis), may also receive medications called nucleos(t)ide analogues. These drugs target hepatitis B specifically and help control that virus, even though they don't directly affect hepatitis D. By keeping hepatitis B under control, these medications can help prevent further liver damage in patients with both infections.
The duration of therapy varies based on individual response. If blood tests still show high levels of the virus after one year of treatment, doctors may recommend continuing pegylated interferon for up to another year. Throughout this time, patients need regular check-ups with blood tests and imaging studies to track how well the treatment is working and watch for complications.
Emerging Treatments in Clinical Trials
Because current standard treatments have limitations, researchers worldwide are testing new medications specifically designed to fight hepatitis D more effectively with fewer side effects. These investigational drugs work through different mechanisms to stop the virus from entering liver cells, replicating, or spreading.
Viral Entry Inhibitors
One of the most promising approaches involves blocking the virus from getting into liver cells in the first place. A medication called bulevirtide (also known by the brand name Hepcludex) was approved in the European Union in 2020 and received full market authorization in 2025. It works by attaching to and blocking a receptor on liver cells called NTCP (sodium taurocholate co-transporting polypeptide), which is the main doorway that hepatitis D uses to enter liver cells.
Bulevirtide has shown promising results in clinical trials. It is approved in several countries including Switzerland, Australia, and the United Kingdom, though it remains an investigational drug in the United States. This medication represents a major advancement because it targets hepatitis D specifically without the harsh side effects seen with interferon.
Other entry inhibitors are following in bulevirtide's footsteps. HH003 is another drug that blocks the NTCP receptor and is currently being studied in clinical trials. Tobevibart is yet another entry inhibitor that works by preventing the virus from attaching to liver cells. Early results show these medications may help reduce virus levels in the blood and improve liver enzyme measurements that indicate liver inflammation.
Pegylated Interferon Lambda
A newer type of interferon called pegylated interferon lambda is being tested as an alternative to the standard pegylated interferon alfa. The key difference is where it works in the body. Interferon lambda acts on Type III interferon receptors, which are found mainly on liver cells rather than throughout the whole body. This targeted approach may mean fewer side effects compared to standard interferon, though it still aims to boost the immune system's ability to fight the virus.
Prenylation Inhibitors
Another class of experimental drugs includes prenylation inhibitors, with lonafarnib being the most studied example. This medication interferes with a chemical process the virus needs to complete its replication cycle inside liver cells. By blocking this step, the drug prevents the virus from making more copies of itself. Lonafarnib has been tested alone and in combination with other drugs. Research suggests it may work even better when combined with pegylated interferon or nucleos(t)ide analogues, creating a synergistic effect where the drugs work together more powerfully than either would alone.
Nucleic Acid Polymers
REP 2139-Mg is an investigational drug that belongs to a category called nucleic acid polymers. These molecules work by blocking the release of hepatitis B surface antigen, which hepatitis D needs to package itself and exit liver cells. Without this surface antigen coating, hepatitis D cannot spread to new cells. Early clinical trials have shown that REP 2139-Mg can reduce viral levels and improve liver health markers in some patients.
RNA Interference Therapies
A cutting-edge approach uses RNA interference technology to silence genes the virus needs to survive. Elebsiran is an experimental drug in this category. It works by using small pieces of RNA to target and destroy viral genetic material, preventing the virus from making proteins it needs. This technology represents a fundamentally different way of fighting viruses compared to traditional medications.
Combination Therapy Trials
Recognizing that attacking the virus through multiple pathways at once might be more effective, researchers are now testing combinations of these new drugs. The SOLSTICE trial is a Phase 2 clinical study evaluating tobevibart used alone or combined with elebsiran. Early results after 24 weeks of monthly treatment showed that more than 50 percent of participants achieved both virologic response (reduced virus levels in blood) and biochemical response (improved liver enzyme levels). This suggests that combination approaches may offer better outcomes than single-drug treatments.
Follow-up studies called ECLIPSE 1, 2, and 3 are being planned to further evaluate the safety and effectiveness of these combination therapies in larger groups of patients over longer periods. These Phase 3 trials will compare the new treatments against standard care to definitively determine whether they represent an improvement.
Trial Phases and Patient Access
Understanding clinical trial phases helps clarify where these treatments are in the development process. Phase I trials involve small groups of healthy volunteers or patients and focus primarily on safety—determining what dose is safe and what side effects might occur. Phase II trials enroll more patients who have the disease and test whether the treatment actually works to reduce viral levels or improve liver health. Phase III trials are large studies comparing the new treatment against the current standard treatment to see which works better.
Clinical trials for hepatitis D are being conducted in various locations worldwide, including the United States, Europe, Asia, and other regions. Eligibility requirements vary by study but typically include having confirmed chronic hepatitis D infection, meeting certain liver health criteria, and not having other conditions that might interfere with the study. People interested in participating can search for open trials through online registries or ask their liver specialist about available options.
Most Common Treatment Methods
Pegylated Interferon Therapy
Weekly injections of pegylated interferon alfa for 48 weeks or longer
Helps the immune system fight the hepatitis D virus
Response rates range from 23 to 57 percent
Can cause side effects including fatigue, flu-like symptoms, weight loss, and depression
Currently the main approved treatment available in most countries including the United States
Viral Entry Inhibitors
Bulevirtide blocks the NTCP receptor on liver cells to prevent viral entry
Approved in the European Union, Switzerland, Australia, and United Kingdom
HH003 and tobevibart are similar entry inhibitors being tested in clinical trials
These medications target hepatitis D specifically with potentially fewer side effects
Nucleos(t)ide Analogues
Medications that target hepatitis B virus specifically
Used in patients with decompensated cirrhosis or high hepatitis B viral loads
Help control hepatitis B to reduce overall liver damage
Do not directly affect hepatitis D virus but support overall liver health
Combination Therapies
Using two or more medications together to attack the virus through multiple mechanisms
Examples include tobevibart combined with elebsiran
Lonafarnib combined with pegylated interferon
Early results suggest better response rates than single-drug approaches
Currently available only through clinical trials
Liver Transplantation
Considered for patients with liver failure or severely damaged liver
Removes the diseased liver and replaces it with a healthy donor liver
Used when medical treatments are not sufficient or disease has progressed too far
Requires evaluation at specialized transplant centers
lightbulb Did you know?
01Hepatitis D is called a "satellite virus" because it's the only virus that can only infect people who already have another virus—it literally cannot survive without hepatitis B.
02Interestingly, when hepatitis D infects liver cells, it actually suppresses hepatitis B replication, though scientists still don't fully understand the mechanism behind this unusual interaction.
03The hepatitis D virus has been recently classified as carcinogenic to humans (Class I) by the International Agency for Research on Cancer, placing it in the same category as hepatitis B and C for causing liver cancer.
Questions people often ask
info This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Austria
